As promising protein kinase inhibitors against multiple types of malignancies, PPP, pacritinib, and SKLB610 showed various degrees of inhibitory effects towards human lung cancer cells (Supplementary Figure S4, Table 1). The gene discussed is WEE1; the disease is lung carcinoma.